{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T18:33:59Z","timestamp":1792953239189,"version":"4.5.0"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s13555-026-01930-8","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:24:43Z","timestamp":1790681083000},"page":"5265-5283","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management Considerations for Patients with Hidradenitis Suppurativa and Lupus Spectrum Disease: A Narrative Review"],"prefix":"10.1007","volume":"16","author":[{"given":"Claire S.","family":"Chung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenan","family":"Kherallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley B.","family":"Crew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stratos","family":"Christianakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1871-571X","authenticated-orcid":false,"given":"Katrina H.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"1930_CR1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jdin.2024.07.017","volume":"17","author":"A Kassels","year":"2024","unstructured":"Kassels A, Park S, Hsiao JL, Kraus CN. Hidradenitis suppurativa is associated with inflammatory arthritis, systemic lupus erythematosus, and other autoimmune diseases: a retrospective population-level study. JAAD Int. 2024;17:55\u20137. https:\/\/doi.org\/10.1016\/j.jdin.2024.07.017.","journal-title":"JAAD Int"},{"key":"1930_CR2","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/jdv.16728","volume":"35","author":"MC Schneeweiss","year":"2021","unstructured":"Schneeweiss MC, Merola JF, Schneeweiss S, Wyss R, Rosmarin D. Risk of connective tissue disease, morphoea and systemic vasculitis in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol JEADV. 2021;35:195\u2013202. https:\/\/doi.org\/10.1111\/jdv.16728.","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"1930_CR3","doi-asserted-by":"publisher","unstructured":"Ross Y, Ballou S. Association of hidradenitis suppurativa with autoimmune disease and autoantibodies. Rheumatol Adv Pract. 2022;6:rkab108. https:\/\/doi.org\/10.1093\/rap\/rkab108","DOI":"10.1093\/rap\/rkab108"},{"key":"1930_CR4","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1016\/j.jaad.2024.09.027","volume":"91","author":"A Charrow","year":"2024","unstructured":"Charrow A, Santiago-Soltero K, Porter M. Biologics in hidradenitis suppurativa: progress and new directions. J Am Acad Dermatol Elsevier. 2024;91:S27-30. https:\/\/doi.org\/10.1016\/j.jaad.2024.09.027.","journal-title":"J Am Acad Dermatol Elsevier"},{"key":"1930_CR5","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.clindermatol.2023.08.020","volume":"41","author":"Z Bukvi\u0107 Mokos","year":"2023","unstructured":"Bukvi\u0107 Mokos Z, Markota \u010cagalj A, Marinovi\u0107 B. Epidemiology of hidradenitis suppurativa. Clin Dermatol. 2023;41:564\u201375. https:\/\/doi.org\/10.1016\/j.clindermatol.2023.08.020.","journal-title":"Clin Dermatol"},{"key":"1930_CR6","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1001\/jamadermatol.2025.2373","volume":"161","author":"D Bouazzi","year":"2025","unstructured":"Bouazzi D, Nielsen SM, Hagan PG, Botvid S, Hove LS, Prens EP, et al. Prevalence of hidradenitis suppurativa: a meta-analysis of global hidradenitis suppurativa atlas studies. JAMA Dermatol. 2025;161:1022\u20138. https:\/\/doi.org\/10.1001\/jamadermatol.2025.2373.","journal-title":"JAMA Dermatol"},{"key":"1930_CR7","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1001\/jamadermatol.2017.0201","volume":"153","author":"A Garg","year":"2017","unstructured":"Garg A, Kirby JS, Lavian J, Lin G, Strunk A. Sex- and age-adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States. JAMA Dermatol. 2017;153:760\u20134. https:\/\/doi.org\/10.1001\/jamadermatol.2017.0201.","journal-title":"JAMA Dermatol"},{"key":"1930_CR8","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/ard-2022-223035","volume":"82","author":"J Tian","year":"2023","unstructured":"Tian J, Zhang D, Yao X, Huang Y, Lu Q. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. Ann Rheum Dis. 2023;82:351\u20136. https:\/\/doi.org\/10.1136\/ard-2022-223035.","journal-title":"Ann Rheum Dis"},{"key":"1930_CR9","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1016\/j.mayocp.2022.06.022","volume":"97","author":"M Hocao\u011flu","year":"2022","unstructured":"Hocao\u011flu M, Davis MDP, Osei-Onomah S-A, Valenzuela-Almada MO, Dabit JY, Duong SQ, et al. Epidemiology of cutaneous lupus erythematosus among adults over four decades (1976\u20132018): a Lupus Midwest Network (LUMEN) study. Mayo Clin Proc. 2022;97:2282\u201390. https:\/\/doi.org\/10.1016\/j.mayocp.2022.06.022.","journal-title":"Mayo Clin Proc"},{"key":"1930_CR10","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1002\/art.41632","volume":"73","author":"PM Izmirly","year":"2021","unstructured":"Izmirly PM, Parton H, Wang L, McCune WJ, Lim SS, Drenkard C, et al. Prevalence of systemic lupus erythematosus in the United States: estimates from a meta-analysis of the Centers for Disease Control and Prevention National Lupus Registries. Arthritis Rheumatol. 2021;73:991\u20136. https:\/\/doi.org\/10.1002\/art.41632.","journal-title":"Arthritis Rheumatol"},{"key":"1930_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2019-000344","volume":"6","author":"P Izmirly","year":"2019","unstructured":"Izmirly P, Buyon J, Belmont HM, Sahl S, Wan I, Salmon J, et al. Population-based prevalence and incidence estimates of primary discoid lupus erythematosus from the Manhattan Lupus Surveillance Program. Lupus Sci Med. 2019;6:e000344. https:\/\/doi.org\/10.1136\/lupus-2019-000344.","journal-title":"Lupus Sci Med"},{"key":"1930_CR12","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1007\/s00296-023-05418-y","volume":"44","author":"T Demirci Yildirim","year":"2024","unstructured":"Demirci Yildirim T, Kahraman A, K\u00f6ken Av\u015far A, Onen F, Akar S, Sari \u0130. Quantitative analysis of JAK\/STAT signaling pathway in patients of inflammatory skin disorders. Rheumatol Int. 2024;44:3009\u201315. https:\/\/doi.org\/10.1007\/s00296-023-05418-y.","journal-title":"Rheumatol Int"},{"key":"1930_CR13","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4049\/jimmunol.182.1.34","volume":"182","author":"SN Kariuki","year":"2009","unstructured":"Kariuki SN, Kirou KA, MacDermott EJ, Barillas-Arias L, Crow MK, Niewold TB. Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-\u03b1 in lupus patients in vivo. J Immunol. 2009;182:34\u20138. https:\/\/doi.org\/10.4049\/jimmunol.182.1.34.","journal-title":"J Immunol"},{"key":"1930_CR14","doi-asserted-by":"publisher","first-page":"8436","DOI":"10.3390\/ijms21228436","volume":"21","author":"E Del Duca","year":"2020","unstructured":"Del Duca E, Morelli P, Bennardo L, Di Raimondo C, Nistic\u00f2 SP. Cytokine pathways and investigational target therapies in hidradenitis suppurativa. Int J Mol Sci. 2020;21:8436. https:\/\/doi.org\/10.3390\/ijms21228436.","journal-title":"Int J Mol Sci"},{"key":"1930_CR15","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.rdc.2021.04.005","volume":"47","author":"JL Paredes","year":"2021","unstructured":"Paredes JL, Fernandez-Ruiz R, Niewold TB. T cells in systemic lupus erythematosus. Rheum Dis Clin North Am. 2021;47:379\u201393. https:\/\/doi.org\/10.1016\/j.rdc.2021.04.005.","journal-title":"Rheum Dis Clin North Am"},{"key":"1930_CR16","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1021\/acs.jproteome.8b00811","volume":"18","author":"F Torell","year":"2019","unstructured":"Torell F, Eketj\u00e4ll S, Idborg H, Jakobsson P-J, Gunnarsson I, Svenungsson E, et al. Cytokine profiles in autoantibody defined subgroups of systemic lupus erythematosus. J Proteome Res American Chemical Society. 2019;18:1208\u201317. https:\/\/doi.org\/10.1021\/acs.jproteome.8b00811.","journal-title":"J Proteome Res American Chemical Society"},{"key":"1930_CR17","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/exd.12098","volume":"22","author":"BC Melnik","year":"2013","unstructured":"Melnik BC, Plewig G. Impaired notch-MKP-1 signalling in hidradenitis suppurativa: an approach to pathogenesis by evidence from translational biology. Exp Dermatol. 2013;22:172\u20137. https:\/\/doi.org\/10.1111\/exd.12098.","journal-title":"Exp Dermatol"},{"key":"1930_CR18","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/9401432","author":"K Fischer","year":"2017","unstructured":"Fischer K, Przepiera-B\u0119dzak H, Sawicki M, Walecka A, Brzosko I, Brzosko M. Serum interleukin-23 in Polish patients with systemic lupus erythematosus: association with lupus nephritis, obesity, and peripheral vascular disease. Mediators Inflamm. 2017. https:\/\/doi.org\/10.1155\/2017\/9401432.","journal-title":"Mediators Inflamm"},{"key":"1930_CR19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12865-015-0070-7","volume":"16","author":"A Zickert","year":"2015","unstructured":"Zickert A, Amoudruz P, Sundstr\u00f6m Y, R\u00f6nnelid J, Malmstr\u00f6m V, Gunnarsson I. IL-17 and IL-23 in lupus nephritis - association to histopathology and response to treatment. BMC Immunol. 2015;16:7. https:\/\/doi.org\/10.1186\/s12865-015-0070-7.","journal-title":"BMC Immunol"},{"key":"1930_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2026.101334","volume":"8","author":"L Deng","year":"2026","unstructured":"Deng L, Wang H, Chen Z, Liu K, Zhu J, Zeng M, et al. Interleukin-17 Inhibitors and the potential association of systemic lupus erythematosus. Kidney Med. 2026;8:101334. https:\/\/doi.org\/10.1016\/j.xkme.2026.101334.","journal-title":"Kidney Med"},{"key":"1930_CR21","doi-asserted-by":"publisher","unstructured":"Hailemichael R, Martin SA, Hwang A, Riley JM, Flood KS, Ren Z. Comorbidities of pediatric patients with hidradenitis suppurativa in the emergency department setting: a cross-sectional study. Pediatr Dermatol [Internet]. [cited 2026 Feb 25];n\/a. https:\/\/doi.org\/10.1111\/pde.70054","DOI":"10.1111\/pde.70054"},{"key":"1930_CR22","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/j.1365-2230.2005.01897.x","volume":"30","author":"A Ah-Weng","year":"2005","unstructured":"Ah-Weng A, Langtry JAA, Velangi S, Evans CD, Douglas WS. Pyoderma gangrenosum associated with hidradenitis suppurativa. Clin Exp Dermatol. 2005;30:669\u201371. https:\/\/doi.org\/10.1111\/j.1365-2230.2005.01897.x.","journal-title":"Clin Exp Dermatol"},{"key":"1930_CR23","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000010186","volume":"97","author":"C Ben David","year":"2018","unstructured":"Ben David C, Bragazzi NL, Watad A, Sharif K, Whitby A, Amital H, et al. Hidradenitis suppurativa associated with systemic lupus erythematosus: a case report. Medicine (Baltimore). 2018;97:e0186. https:\/\/doi.org\/10.1097\/MD.0000000000010186.","journal-title":"Medicine (Baltimore)"},{"key":"1930_CR24","doi-asserted-by":"publisher","unstructured":"Nazzaro G, Muratori S. Hidradenitis suppurativa associated with systemic lupus erythematosus and psoriasis: a therapeutical challenge. Ital J Dermatol Venereol. 2021;156:13\u20134. https:\/\/doi.org\/10.23736\/S2784-8671.19.06209-6","DOI":"10.23736\/S2784-8671.19.06209-6"},{"key":"1930_CR25","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s13555-025-01569-x","volume":"16","author":"FJ Melgosa Ramos","year":"2026","unstructured":"Melgosa Ramos FJ, Mart\u00ednez Ruiz E, Galarreta Pascual M, Sanz-Motilva V, Martorell A. Secukinumab plus upadacitinib for the treatment of severe hidradenitis suppurativa and associated immune-mediated comorbidities: a case series. Dermatol Ther. 2026;16:659\u201367. https:\/\/doi.org\/10.1007\/s13555-025-01569-x.","journal-title":"Dermatol Ther"},{"key":"1930_CR26","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s00296-025-05828-0","volume":"45","author":"MM Berikopoulou","year":"2025","unstructured":"Berikopoulou MM, Konstantopoulou A, Argyrakis S, Theochari M, Drosatou P, Messaritaki A, et al. \u0397idradenitis suppurativa associated with autoimmunity in children and adolescents; a case-based review. Rheumatol Int. 2025;45:83. https:\/\/doi.org\/10.1007\/s00296-025-05828-0.","journal-title":"Rheumatol Int"},{"key":"1930_CR27","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1001\/archdermatol.2009.49","volume":"145","author":"R Blanco","year":"2009","unstructured":"Blanco R, Mart\u00ednez-Taboada VM, Villa I, Gonz\u00e1lez-Vela MC, Fern\u00e1ndez-Llaca H, Agudo M, et al. Long-term successful adalimumab therapy in severe hidradenitis suppurativa. Arch Dermatol. 2009;145:580\u20134. https:\/\/doi.org\/10.1001\/archdermatol.2009.49.","journal-title":"Arch Dermatol"},{"key":"1930_CR28","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1111\/ijd.14674","volume":"59","author":"D Turk","year":"2020","unstructured":"Turk D, Vellaichamy G, Lyons AB, Parks-Miller A, Nelson T, Meysami A, et al. Anti-tumor necrosis factor (TNF)-induced lupus in a patient with hidradenitis suppurativa. Int J Dermatol. 2020;59:e73\u20134. https:\/\/doi.org\/10.1111\/ijd.14674.","journal-title":"Int J Dermatol"},{"key":"1930_CR29","doi-asserted-by":"publisher","unstructured":"Boskovic S, Repetto F, Giordano S, Sciamarrelli N, Conti L, Ortoncelli M, et al. A case of lupus-like reaction following the administration of anti-TNF\u03b1 in a patient with hidradenitis suppurativa. Ital J Dermatol Venereol [Internet]. 2025 [cited 2026 June 1];160. https:\/\/doi.org\/10.23736\/S2784-8671.25.08171-X","DOI":"10.23736\/S2784-8671.25.08171-X"},{"key":"1930_CR30","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.jaad.2025.10.149","volume":"94","author":"ML Porter","year":"2026","unstructured":"Porter ML, Ferreira-Cornwell MC, Wang M, Nawaz H, Gooderham MJ. Efficacy and safety of ruxolitinib cream in patients with mild to moderate hidradenitis suppurativa: results from a randomized, double-blind, vehicle-controlled phase 2 study. J Am Acad Dermatol Elsevier. 2026;94:879\u201387. https:\/\/doi.org\/10.1016\/j.jaad.2025.10.149.","journal-title":"J Am Acad Dermatol Elsevier"},{"key":"1930_CR31","doi-asserted-by":"publisher","unstructured":"Pascual JC, Encabo B, Ruiz de Apodaca RF, Romero D, Selva J, Jemec GB. Topical 15% resorcinol for hidradenitis suppurativa: an uncontrolled prospective trial with clinical and ultrasonographic follow-up. J Am Acad Dermatol. 2017;77:1175\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2017.07.008","DOI":"10.1016\/j.jaad.2017.07.008"},{"key":"1930_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15439","volume":"35","author":"E Molinelli","year":"2022","unstructured":"Molinelli E, Brisigotti V, Simonetti O, Sapigni C, D\u2019Agostino GM, Rizzetto G, et al. Efficacy and safety of topical resorcinol 15% versus topical clindamycin 1% in the management of mild-to-moderate hidradenitis suppurativa: a retrospective study. Dermatol Ther. 2022;35:e15439. https:\/\/doi.org\/10.1111\/dth.15439.","journal-title":"Dermatol Ther"},{"key":"1930_CR33","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jdcr.2022.08.038","volume":"28","author":"JJ Park","year":"2022","unstructured":"Park JJ, Little AJ, Vesely MD. Treatment of cutaneous lupus with topical ruxolitinib cream. JAAD Case Rep. 2022;28:133\u20135. https:\/\/doi.org\/10.1016\/j.jdcr.2022.08.038.","journal-title":"JAAD Case Rep"},{"key":"1930_CR34","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1177\/09612033211033985","volume":"30","author":"S Izuka","year":"2021","unstructured":"Izuka S, Yamashita H, Takahashi Y, Kaneko H. Adverse drug reactions to trimethoprim-sulfamethoxazole in systemic lupus erythematosus. Lupus. 2021;30:1679\u201383. https:\/\/doi.org\/10.1177\/09612033211033985.","journal-title":"Lupus"},{"key":"1930_CR35","first-page":"53","volume":"60","author":"J Cudmore","year":"2014","unstructured":"Cudmore J, Seftel M, Sisler J, Zarychanski R. Methotrexate and trimethoprim-sulfamethoxazole. Can Fam Physician. 2014;60:53\u20136.","journal-title":"Can Fam Physician"},{"key":"1930_CR36","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1046\/j.1365-2230.2001.00809.x","volume":"26","author":"GK Patel","year":"2001","unstructured":"Patel GK, Anstey AV. Rifampicin-induced lupus erythematosus. Clin Exp Dermatol. 2001;26:260\u20132. https:\/\/doi.org\/10.1046\/j.1365-2230.2001.00809.x.","journal-title":"Clin Exp Dermatol"},{"key":"1930_CR37","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/S0140-6736(05)62102-2","volume":"349","author":"SE Berning","year":"1997","unstructured":"Berning SE, Iseman MD. Rifamycin-induced lupus syndrome The Lancet Elsevier. 1997;349:1521\u20132. https:\/\/doi.org\/10.1016\/S0140-6736(05)62102-2.","journal-title":"Rifamycin-induced lupus syndrome The Lancet Elsevier"},{"key":"1930_CR38","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/j.ekir.2023.02.129","volume":"8","author":"M Chhakchhuak","year":"2023","unstructured":"Chhakchhuak M, Khiangte L, Renthlei L. WCN23-0198 metronidazole induced lupus erythematosus: a rare case with novel clinical presentation. Kidney Int Rep. 2023;8:S58\u20139. https:\/\/doi.org\/10.1016\/j.ekir.2023.02.129.","journal-title":"Kidney Int Rep"},{"key":"1930_CR39","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/j.1365-2133.2007.08056.x","volume":"157","author":"DJ Margolis","year":"2007","unstructured":"Margolis DJ, Hoffstad O, Bilker W. Association or lack of association between tetracycline class antibiotics used for acne vulgaris and lupus erythematosus. Br J Dermatol. 2007;157:540\u20136. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.08056.x.","journal-title":"Br J Dermatol"},{"key":"1930_CR40","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1159\/000018387","volume":"200","author":"RG Schlienger","year":"2000","unstructured":"Schlienger RG, Bircher AJ, Meier CR. Minocycline-induced lupus\u202f: a systematic review. Dermatology. 2000;200:223\u201331. https:\/\/doi.org\/10.1159\/000018387.","journal-title":"Dermatology"},{"key":"1930_CR41","doi-asserted-by":"publisher","first-page":"7353644","DOI":"10.1155\/2023\/7353644","volume":"2023","author":"KQ Newman","year":"2023","unstructured":"Newman KQ, Castles CG. Use of doxycycline in a patient following minocycline-induced lupus. Case Rep Rheumatol. 2023;2023:7353644. https:\/\/doi.org\/10.1155\/2023\/7353644.","journal-title":"Case Rep Rheumatol"},{"key":"1930_CR42","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s11096-018-0661-5","volume":"40","author":"D AlSaad","year":"2018","unstructured":"AlSaad D, Lee BH, Al-Obaidly S. Finasteride use during pregnancy and early neonatal outcome: a case report. Int J Clin Pharm. 2018;40:803\u20135. https:\/\/doi.org\/10.1007\/s11096-018-0661-5.","journal-title":"Int J Clin Pharm"},{"key":"1930_CR43","doi-asserted-by":"publisher","first-page":"e210","DOI":"10.1016\/S2665-9913(20)30004-7","volume":"2","author":"F Sun","year":"2020","unstructured":"Sun F, Wang HJ, Liu Z, Geng S, Wang HT, Wang X, et al. Safety and efficacy of metformin in systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Rheumatol. 2020;2:e210\u20136. https:\/\/doi.org\/10.1016\/S2665-9913(20)30004-7.","journal-title":"Lancet Rheumatol"},{"key":"1930_CR44","first-page":"198","volume":"24","author":"MS Uddin","year":"1979","unstructured":"Uddin MS, Lynfield YL, Grosberg SJ, Stiefler R. Cutaneous reaction to spironolactone resembling lupus erythematosus. Cutis. 1979;24:198\u2013200.","journal-title":"Cutis"},{"key":"1930_CR45","first-page":"448","volume":"5","author":"RL Travers","year":"1978","unstructured":"Travers RL, Hughes GR. Oral contraceptive therapy and systemic lupus erythematosus. J Rheumatol. 1978;5:448\u201351.","journal-title":"J Rheumatol"},{"key":"1930_CR46","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/art.41191","volume":"72","author":"LR Sammaritano","year":"2020","unstructured":"Sammaritano LR, Bermas BL, Chakravarty EE, Chambers C, Clowse MEB, Lockshin MD, et al. 2020 American college of rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol. 2020;72:529\u201356. https:\/\/doi.org\/10.1002\/art.41191.","journal-title":"Arthritis Rheumatol"},{"key":"1930_CR47","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1002\/art.1780250603","volume":"25","author":"P Jungers","year":"1982","unstructured":"Jungers P, Dougados M, P\u00e9lissier C, Kuttenn F, Tron F, Lesavre P, et al. Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus. Arthritis Rheum. 1982;25:618\u201323. https:\/\/doi.org\/10.1002\/art.1780250603.","journal-title":"Arthritis Rheum"},{"key":"1930_CR48","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1001\/jamadermatol.2025.2723","volume":"161","author":"L Gouvrion","year":"2025","unstructured":"Gouvrion L, Delage M, Villani AP, Le Naour S, Fite C, Cassius C, et al. Glucagon-like peptide-1 receptor agonists in hidradenitis suppurativa. JAMA Dermatol. 2025;161:1084\u20136. https:\/\/doi.org\/10.1001\/jamadermatol.2025.2723.","journal-title":"JAMA Dermatol"},{"key":"1930_CR49","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jaad.2024.11.039","volume":"92","author":"MA Hill","year":"2025","unstructured":"Hill MA, Bordeaux JS. Semaglutide use for decreasing hidradenitis suppurativa resource utilization: a retrospective cohort study utilizing TriNetX. J Am Acad Dermatol. 2025;92:896\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2024.11.039.","journal-title":"J Am Acad Dermatol"},{"key":"1930_CR50","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.amjmed.2026.02.016","volume":"139","author":"M Hanif","year":"2026","unstructured":"Hanif M, Nagarajan JS, Murphy R, Sah SP, Ye S, Perl A, et al. Glucagon-like peptide-1 receptor agonist and lupus nephritis in systemic lupus erythematosus with type 2 diabetes. Am J Med. 2026;139:769-781.e8. https:\/\/doi.org\/10.1016\/j.amjmed.2026.02.016.","journal-title":"Am J Med"},{"key":"1930_CR51","doi-asserted-by":"publisher","unstructured":"Jorge A, Patel AV, Zhou B, Zhang L, Choi H. Glucagon-like peptide-1 receptor agonist use and the risk of adverse cardiac and kidney outcomes among patients with systemic lupus erythematosus and lupus nephritis. Arthritis Rheumatol. Hoboken, N.J.; 2026;78:665\u201371. https:\/\/doi.org\/10.1002\/art.43403","DOI":"10.1002\/art.43403"},{"key":"1930_CR52","doi-asserted-by":"publisher","unstructured":"Nazzicone K, Sidiropoulos M, O\u2019Toole A. From prescription to predicament: a case of semaglutide-induced discoid lupus erythematosus in an adult male patient. Cureus. 17:e81663. https:\/\/doi.org\/10.7759\/cureus.81663","DOI":"10.7759\/cureus.81663"},{"key":"1930_CR53","doi-asserted-by":"publisher","unstructured":"Carlucci PM, Cohen B, Saxena A, Belmont HM, Masson M, Gold HT, et al. A retrospective evaluation of glucagon-like peptide-1 receptor agonists in systemic lupus erythematosus patients. Rheumatology. Oxford, England; 2025;64:3085\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/keae547","DOI":"10.1093\/rheumatology\/keae547"},{"key":"1930_CR54","doi-asserted-by":"publisher","unstructured":"Nagra D, Zuckerman B, Odia J, Patel S, Ong M, Adas M, et al. The role of interleukin-17 inhibition in systemic lupus erythematosus\u2014paradoxical hindrance or new therapeutic potential? Results from a systematic literature review and mendelian randomization. Front Immunol. 17:1706949. https:\/\/doi.org\/10.3389\/fimmu.2026.1706949","DOI":"10.3389\/fimmu.2026.1706949"},{"key":"1930_CR55","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jdcr.2020.02.013","volume":"6","author":"G Chatzimichail","year":"2020","unstructured":"Chatzimichail G, Zillikens D, Tha\u00e7i D. Secukinumab-induced chronic discoid lupus erythematosus. JAAD Case Rep. 2020;6:362\u20134. https:\/\/doi.org\/10.1016\/j.jdcr.2020.02.013.","journal-title":"JAAD Case Rep"},{"key":"1930_CR56","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1177\/09612033241242698","volume":"33","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Hu Z. Membranous lupus nephritis secondary to secukinumab therapy: a case report and literature review. Lupus. 2024;33:644\u20139. https:\/\/doi.org\/10.1177\/09612033241242698.","journal-title":"Lupus"},{"key":"1930_CR57","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1136\/ard.2005.043166","volume":"65","author":"MH Schiff","year":"2006","unstructured":"Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpatrick SB, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65:889\u201394. https:\/\/doi.org\/10.1136\/ard.2005.043166.","journal-title":"Ann Rheum Dis"},{"key":"1930_CR58","doi-asserted-by":"publisher","first-page":"R545","DOI":"10.1186\/ar1715","volume":"7","author":"M De Bandt","year":"2005","unstructured":"De Bandt M, Sibilia J, Le Lo\u00ebt X, Prouzeau S, Fautrel B, Marcelli C, et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther. 2005;7:R545\u201351. https:\/\/doi.org\/10.1186\/ar1715.","journal-title":"Arthritis Res Ther"},{"key":"1930_CR59","doi-asserted-by":"publisher","unstructured":"2025 American College of Rheumatology (ACR) guideline for the treatment of systemic lupus erythematosus. [cited 2026 May 16]; https:\/\/doi.org\/10.1002\/acr.25690","DOI":"10.1002\/acr.25690"},{"key":"1930_CR60","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.adengl.2020.10.023","volume":"111","author":"B Duarte","year":"2020","unstructured":"Duarte B, Cunha N, Lencastre A, Cabete J. Systemic steroids in the management of moderate-to-severe hidradenitis suppurativa. Actas Dermo-Sifiliogr\u00e1ficas Engl Ed. 2020;111:879\u201383. https:\/\/doi.org\/10.1016\/j.adengl.2020.10.023.","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas Engl Ed"},{"key":"1930_CR61","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.jaad.2016.06.001","volume":"75","author":"D Wong","year":"2016","unstructured":"Wong D, Walsh S, Alhusayen R. Low-dose systemic corticosteroid treatment for recalcitrant hidradenitis suppurativa. J Am Acad Dermatol. 2016;75:1059\u201362. https:\/\/doi.org\/10.1016\/j.jaad.2016.06.001.","journal-title":"J Am Acad Dermatol"},{"key":"1930_CR62","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jaad.2018.06.046","volume":"80","author":"ARJV Vossen","year":"2019","unstructured":"Vossen ARJV, van Doorn MBA, van der Zee HH, Prens EP. Apremilast for moderate hidradenitis suppurativa: results of a randomized controlled trial. J Am Acad Dermatol. 2019;80:80\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2018.06.046.","journal-title":"J Am Acad Dermatol"},{"key":"1930_CR63","first-page":"1224","volume":"11","author":"A De Souza","year":"2012","unstructured":"De Souza A, Strober BE, Merola JF, Oliver S, Franks AG. Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study. J Drugs Dermatol JDD. 2012;11:1224\u20136.","journal-title":"J Drugs Dermatol JDD"},{"key":"1930_CR64","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1111\/ijd.16804","volume":"62","author":"I L\u00f3pez Riquelme","year":"2023","unstructured":"L\u00f3pez Riquelme I, Fern\u00e1ndez Ballesteros MD, Perea Polak A, Serrano Ordo\u00f1ez A, Mart\u00ednez PL. Azathioprine in hidradenitis suppurativa with inflammatory phenotype: a case series of 11 patients. Int J Dermatol. 2023;62:1300\u20133. https:\/\/doi.org\/10.1111\/ijd.16804.","journal-title":"Int J Dermatol"},{"key":"1930_CR65","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/bjd.14086","volume":"174","author":"M Nazary","year":"2016","unstructured":"Nazary M, Prens EP, Boer J. Azathioprine lacks efficacy in hidradenitis suppurativa: a retrospective study of nine patients. Br J Dermatol. 2016;174:639\u201341. https:\/\/doi.org\/10.1111\/bjd.14086.","journal-title":"Br J Dermatol"},{"key":"1930_CR66","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3109\/09546634.2015.1088128","volume":"27","author":"MD Anderson","year":"2016","unstructured":"Anderson MD, Zauli S, Bettoli V, Boer J, Jemec GBE. Cyclosporine treatment of severe Hidradenitis suppurativa\u2013a case series. J Dermatol Treat. 2016;27:247\u201350. https:\/\/doi.org\/10.3109\/09546634.2015.1088128.","journal-title":"J Dermatol Treat"},{"key":"1930_CR67","doi-asserted-by":"publisher","first-page":"e278","DOI":"10.1016\/j.jaad.2012.06.011","volume":"67","author":"L Bianchi","year":"2012","unstructured":"Bianchi L, Hansel K, Stingeni L. Recalcitrant severe hidradenitis suppurativa successfully treated with cyclosporine A. J Am Acad Dermatol Elsevier. 2012;67:e278\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2012.06.011.","journal-title":"J Am Acad Dermatol Elsevier"},{"key":"1930_CR68","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jdcr.2026.02.049","volume":"72","author":"R Rookwood","year":"2026","unstructured":"Rookwood R, Islam Z, Schiraldi N, Romanelli S, Salloum L, Campton K, et al. Successful methotrexate rescue following antibody-mediated infliximab failure for treatment-refractory hidradenitis suppurativa. JAAD Case Rep. 2026;72:52\u20135. https:\/\/doi.org\/10.1016\/j.jdcr.2026.02.049.","journal-title":"JAAD Case Rep"},{"key":"1930_CR69","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ijwd.2020.02.007","volume":"6","author":"KT Savage","year":"2020","unstructured":"Savage KT, Brant EG, Rosales Santillan M, Morss PC, Salian P, Flood KS, et al. Methotrexate shows benefit in a subset of patients with severe hidradenitis suppurativa. Int J Womens Dermatol. 2020;6:159\u201363. https:\/\/doi.org\/10.1016\/j.ijwd.2020.02.007.","journal-title":"Int J Womens Dermatol"},{"key":"1930_CR70","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1093\/bjd\/ljae330","volume":"192","author":"RL Imhof","year":"2025","unstructured":"Imhof RL, Dai C, Alavi A, Sokumbi O. Management and outcomes of hidradenitis suppurativa in solid organ transplant recipients. Br J Dermatol. 2025;192:347\u20139. https:\/\/doi.org\/10.1093\/bjd\/ljae330.","journal-title":"Br J Dermatol"},{"key":"1930_CR71","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0190-9622(99)70530-X","volume":"40","author":"J Boer","year":"1999","unstructured":"Boer J, van Gemert MJP. Long-term results of isotretinoin in the treatment of 68 patients with hidradenitis suppurativa. J Am Acad Dermatol. 1999;40:73\u20136. https:\/\/doi.org\/10.1016\/S0190-9622(99)70530-X.","journal-title":"J Am Acad Dermatol"},{"key":"1930_CR72","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/S0190-9622(84)70199-X","volume":"11","author":"CH Dicken","year":"1984","unstructured":"Dicken CH, Powell ST, Spear KL. Evaluation of isotretinoin treatment of hidradenitis suppurativa. J Am Acad Dermatol Elsevier. 1984;11:500\u20132. https:\/\/doi.org\/10.1016\/S0190-9622(84)70199-X.","journal-title":"J Am Acad Dermatol Elsevier"},{"key":"1930_CR73","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1159\/000182261","volume":"218","author":"A Soria","year":"2008","unstructured":"Soria A, Canoui-Poitrine F, Wolkenstein P, Poli F, Gabison G, Pouget F, et al. Absence of efficacy of oral isotretinoin in hidradenitis suppurativa: a retrospective study based on patients\u2019 outcome assessment. Dermatology. 2008;218:134\u20135. https:\/\/doi.org\/10.1159\/000182261.","journal-title":"Dermatology"},{"key":"1930_CR74","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1053\/j.ajkd.2009.06.012","volume":"55","author":"K Kinoshita","year":"2010","unstructured":"Kinoshita K, Kishimoto K, Shimazu H, Nozaki Y, Sugiyama M, Ikoma S, et al. Successful treatment with retinoids in patients with lupus nephritis. Am J Kidney Dis. 2010;55:344\u20137. https:\/\/doi.org\/10.1053\/j.ajkd.2009.06.012.","journal-title":"Am J Kidney Dis"},{"key":"1930_CR75","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3109\/15569527.2016.1169284","volume":"36","author":"B Mizio\u0142ek","year":"2017","unstructured":"Mizio\u0142ek B, Bergler-Czop B, Sta\u0144kowska A, Brzezi\u0144ska-Wcis\u0142o L. The safety of isotretinoin in patients with lupus nephritis: a comprehensive review. Cutan Ocul Toxicol. 2017;36:77\u201384. https:\/\/doi.org\/10.3109\/15569527.2016.1169284.","journal-title":"Cutan Ocul Toxicol"},{"key":"1930_CR76","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1001\/archderm.1986.01660140060018","volume":"122","author":"RC Newton","year":"1986","unstructured":"Newton RC, Jorizzo JL, Solomon AR Jr, Sanchez RL, Daniels JC, Bell JD, et al. Mechanism-oriented assessment of isotretinoin in chronic or subacute cutaneous lupus erythematosus. Arch Dermatol. 1986;122:170\u20136. https:\/\/doi.org\/10.1001\/archderm.1986.01660140060018.","journal-title":"Arch Dermatol"},{"key":"1930_CR77","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.70082","volume":"137","author":"I Ates","year":"2025","unstructured":"Ates I, Sahin H, Irham LM, Yilmaz S, Suzen S. The role of hydroxychloroquine in the management of rheumatic disorders: a comprehensive review. Basic Clin Pharmacol Toxicol. 2025;137:e70082. https:\/\/doi.org\/10.1111\/bcpt.70082.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"1930_CR78","doi-asserted-by":"publisher","unstructured":"Sammaritano LR, Askanase A, Bermas BL, Dall\u2019Era M, Duarte-Garc\u00eda A, Hiraki LT, et al. 2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis. Arthritis Rheumatol. 2025;77:1115\u201335. https:\/\/doi.org\/10.1002\/art.43212","DOI":"10.1002\/art.43212"},{"key":"1930_CR79","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1093\/skinhd\/vzaf058","volume":"5","author":"C Gewiss","year":"2025","unstructured":"Gewiss C, Steinmetz OM, Roth L, Augustin M, Ben-Anaya N. Effective management of psoriasis and psoriatic arthritis in a patient with systemic lupus erythematosus using deucravacitinib, mycophenolate mofetil and hydroxychloroquine. Skin Health Dis. 2025;5:403\u20135. https:\/\/doi.org\/10.1093\/skinhd\/vzaf058.","journal-title":"Skin Health Dis"},{"key":"1930_CR80","unstructured":"AstraZeneca. A multicenter, randomized, double blind, placebo controlled, phase iii study to evaluate the efficacy and safety of anifrolumab in adults with chronic and/or subacute cutaneous lupus erythematosus who are refractory and/or intolerant to antimalarial therapy. [Internet]. clinicaltrials.gov; 2026 Apr. Report No.: NCT06015737. https:\/\/clinicaltrials.gov\/study\/NCT06015737. Accessed 17 May 2026"},{"key":"1930_CR81","unstructured":"University of North Carolina, Chapel Hill. A prospective open-label trial examining the efficacy and safety of anifrolumab for hidradenitis suppurativa (HS) [Internet]. clinicaltrials.gov; 2026 Feb. Report No.: NCT06374212. https:\/\/clinicaltrials.gov\/study\/NCT06374212. Accessed 17 May 2026"},{"key":"1930_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103818","volume":"24","author":"N Heidari","year":"2025","unstructured":"Heidari N, Heidari A, Eghbali S, Pishraft-Sabet H, Hajikarim-Hamedani A, Ghane Y, et al. The role of interleukin inhibitors in the treatment of hidradenitis suppurativa; a systematic review of clinical trials. Autoimmun Rev. 2025;24:103818. https:\/\/doi.org\/10.1016\/j.autrev.2025.103818.","journal-title":"Autoimmun Rev"},{"key":"1930_CR83","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.2147\/CCID.S418748","volume":"16","author":"F Martora","year":"2023","unstructured":"Martora F, Scalvenzi M, Battista T, Fornaro L, Potestio L, Ruggiero A, et al. Guselkumab, Risankizumab, and Tildrakizumab in the Management of hidradenitis suppurativa: a review of existing trials and real-life data. Clin Cosmet Investig Dermatol. 2023;16:2525\u201336. https:\/\/doi.org\/10.2147\/CCID.S418748.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"1930_CR84","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jdcr.2022.05.039","volume":"25","author":"C Barber","year":"2022","unstructured":"Barber C, Song EJ. New-onset systemic lupus erythematous in a patient receiving risankizumab for psoriasis. JAAD Case Rep. 2022;25:104\u20136. https:\/\/doi.org\/10.1016\/j.jdcr.2022.05.039.","journal-title":"JAAD Case Rep"},{"key":"1930_CR85","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1093\/rheumatology\/keae647","volume":"64","author":"H-J Anders","year":"2025","unstructured":"Anders H-J, Chan TM, Sanchez-Guerrero J, Wofsy D, Bensley K, Kim L, et al. Efficacy and safety of guselkumab in patients with active lupus nephritis: results from a phase 2, randomized, placebo-controlled study. Rheumatology (Oxford). 2025;64:2731\u201340. https:\/\/doi.org\/10.1093\/rheumatology\/keae647.","journal-title":"Rheumatology (Oxford)"},{"key":"1930_CR86","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1007\/s13555-024-01207-y","volume":"14","author":"R Masson","year":"2024","unstructured":"Masson R, Seivright J, Grogan T, Atluri S, Hamzavi I, Hogeling M, et al. Ustekinumab in hidradenitis suppurativa: a systematic review and meta-analysis. Dermatol Ther. 2024;14:1901\u201316. https:\/\/doi.org\/10.1007\/s13555-024-01207-y.","journal-title":"Dermatol Ther"},{"key":"1930_CR87","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/S0140-6736(18)32167-6","volume":"392","author":"RF van Vollenhoven","year":"2018","unstructured":"van Vollenhoven RF, Hahn BH, Tsokos GC, Wagner CL, Lipsky P, Touma Z, et al. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. Lancet. 2018;392:1330\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(18)32167-6.","journal-title":"Lancet"},{"key":"1930_CR88","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.82379","volume":"17","author":"N Barlas","year":"2025","unstructured":"Barlas N, Kaur IP, Kuzhuppilly Arcilla C, Kaeley GS, Thway M. Effective treatment of macrophage activation syndrome linked to systemic lupus erythematosus using interleukin-1 inhibitor. Cureus. 2025;17:e82379. https:\/\/doi.org\/10.7759\/cureus.82379.","journal-title":"Cureus"},{"key":"1930_CR89","doi-asserted-by":"publisher","unstructured":"Dein E, Ingolia A, Connolly C, Manno R, Timlin H. Anakinra for recurrent fevers in systemic lupus erythematosus. Cureus. 10:e3782. https:\/\/doi.org\/10.7759\/cureus.3782","DOI":"10.7759\/cureus.3782"},{"key":"1930_CR90","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1136\/ard.2004.025858","volume":"64","author":"B Ostendorf","year":"2005","unstructured":"Ostendorf B, Iking-Konert C, Kurz K, Jung G, Sander O, Schneider M. Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann Rheum Dis. 2005;64:630\u20133. https:\/\/doi.org\/10.1136\/ard.2004.025858.","journal-title":"Ann Rheum Dis"},{"key":"1930_CR91","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1001\/jamadermatol.2015.3903","volume":"152","author":"V Tzanetakou","year":"2016","unstructured":"Tzanetakou V, Kanni T, Giatrakou S, Katoulis A, Papadavid E, Netea MG, et al. Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial. JAMA Dermatol. 2016;152:52\u20139. https:\/\/doi.org\/10.1001\/jamadermatol.2015.3903.","journal-title":"JAMA Dermatol"},{"key":"1930_CR92","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1001\/jamadermatol.2017.3295","volume":"153","author":"Errors in Reported Data","year":"2017","unstructured":"Errors in reported data. JAMA Dermatol. 2017;153:950. https:\/\/doi.org\/10.1001\/jamadermatol.2017.3295.","journal-title":"JAMA Dermatol"},{"key":"1930_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103440","volume":"22","author":"L Ma","year":"2023","unstructured":"Ma L, Peng L, Zhao J, Bai W, Jiang N, Zhang S, et al. Efficacy and safety of Janus kinase inhibitors in systemic and cutaneous lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev. 2023;22:103440. https:\/\/doi.org\/10.1016\/j.autrev.2023.103440.","journal-title":"Autoimmun Rev"},{"key":"1930_CR94","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jaad.2022.12.037","volume":"89","author":"A Abduelmula","year":"2023","unstructured":"Abduelmula A, Sood S, Mufti A, Hinek A, Yeung J. Management of cutaneous lupus erythematosus with Janus kinase inhibitor therapy: an evidence-based review. J Am Acad Dermatol. 2023;89:130\u20131. https:\/\/doi.org\/10.1016\/j.jaad.2022.12.037.","journal-title":"J Am Acad Dermatol"},{"key":"1930_CR95","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.jaad.2024.12.046","volume":"92","author":"LS Ackerman","year":"2025","unstructured":"Ackerman LS, Schlosser BJ, Zhan T, Prajapati VH, Fretzin S, Takahashi H, et al. Improvements in moderate-to-severe hidradenitis suppurativa with upadacitinib: results from a phase 2, randomized, placebo-controlled study. J Am Acad Dermatol Elsevier. 2025;92:1252\u201360. https:\/\/doi.org\/10.1016\/j.jaad.2024.12.046.","journal-title":"J Am Acad Dermatol Elsevier"},{"key":"1930_CR96","doi-asserted-by":"publisher","unstructured":"Abstracts of the 10th Annual Symposium on Hidradenitis Suppurativa Advances 2025. Dermatol Ther [Internet]. 2025 [cited 2025 Dec 17]; https:\/\/doi.org\/10.1007\/s13555-025-01579-9","DOI":"10.1007\/s13555-025-01579-9"},{"key":"1930_CR97","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.ard.2025.06.141","volume":"84","author":"JF Merola","year":"2025","unstructured":"Merola JF, Gottlieb AB, Aranow C, Chasset F, Wenzel J, Fiorentino D, et al. POS0781 efficacy and safety of oral deucravacitinib in patients with cutaneous manifestations of lupus erythematosus: results from paisley CLE, a global, randomized, placebo-controlled, phase 2 trial. Ann Rheum Dis. 2025;84:940\u20131. https:\/\/doi.org\/10.1016\/j.ard.2025.06.141.","journal-title":"Ann Rheum Dis"},{"key":"1930_CR98","doi-asserted-by":"publisher","first-page":"5830","DOI":"10.1007\/s12325-025-03299-0","volume":"42","author":"C Arriens","year":"2025","unstructured":"Arriens C, Morand EF, Askanase AD, Furie R, van Vollenhoven RF, Tanaka Y, et al. Design of two randomized, placebo-controlled, phase 3 trials of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in systemic lupus erythematosus. Adv Ther. 2025;42:5830\u201344. https:\/\/doi.org\/10.1007\/s12325-025-03299-0.","journal-title":"Adv Ther"},{"key":"1930_CR99","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jdcr.2023.07.030","volume":"39","author":"N Bouch\u00e9","year":"2023","unstructured":"Bouch\u00e9 N, Al-Saedy MA, Song EJ. Successful treatment of refractory subacute cutaneous lupus erythematosus with deucravacitinib. JAAD Case Rep. 2023;39:93\u20135. https:\/\/doi.org\/10.1016\/j.jdcr.2023.07.030.","journal-title":"JAAD Case Rep"},{"key":"1930_CR100","doi-asserted-by":"publisher","unstructured":"Kimball AB, Peeva E, Forman S, Moiin A, Khattri S, Porter ML, et al. Brepocitinib, zimlovisertib, and ropsacitinib in hidradenitis suppurativa. NEJM Evid. Massachusetts Medical Society; 2024;3:EVIDoa2300155. https:\/\/doi.org\/10.1056\/EVIDoa2300155","DOI":"10.1056\/EVIDoa2300155"},{"key":"1930_CR101","unstructured":"Roivant. Roivant and priovant announce results from phase 2 study of oral brepocitinib in systemic lupus erythematosus | Roivant Sciences Ltd. [Internet]. [cited 2026 May 17]. https:\/\/investor.roivant.com\/news-releases\/news-release-details\/roivant-and-priovant-announce-results-phase-2-study-oral\/. Accessed 17 May 2026"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01930-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01930-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01930-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T18:00:53Z","timestamp":1792951253000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01930-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":101,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1930"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01930-8","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"assertion":[{"value":"16 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ashley B. Crew has served as an investigator or advisor for Incyte and AstraZeneca and Priovant. Jennifer L. Hsiao is on the board of directors for the HS Foundation, and has served as an advisor, investigator, and\/or speaker for AbbVie, Amgen, Aclaris, AstraZeneca, Boehringer Ingelheim, Galderma, Incyte, Insmed, Moonlake, Navigator Medicines, Novartis, Oruka Therapeutics, Pfizer, Sanofi, Regeneron, and UCB. Jennifer L. Hsiao is an editor-in-chief for\n                      Dermatology and Therapy\n                      . Jennifer L. Hsiao was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Katrina H. Lee has served as an advisory board member and\/or investigator for Novartis and Incyte. Claire S. Chung, Kenan Kherallah, and Stratos Christianakis report no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}